ibogaine

A North Carolina veteran described ibogaine as a turning point in his life after serving in the Army during Afghanistan and Iraq wars. He sought psychedelic-assisted therapy through Veterans Exploring Treatment Solutions (VETS) and received treatment in Mexico, where ibogaine is available despite being illegal in the U.S.

More states are expanding PTSD treatment options for first responders by adopting laws that include medical marijuana protections and psychedelic therapy research. Maryland and Ohio have enacted measures to support mental health, while Connecticut and Missouri are exploring psilocybin and ibogaine therapies for eligible first responders and veterans.

Scientists are exploring synthetic modifications of natural psychedelic compounds like ibogaine and psilocybin to reduce risks and enhance therapeutic benefits. A yellow mushroom in China's Yunnan province induces consistent 'lilliputian hallucinations,' sparking interest in engineering safer, more effective psychedelics.

A Republican state Rep. Jaime Green proposes using opioid settlement funds to conduct clinical trials on ibogaine, a Schedule 1 psychedelic drug, to treat addiction and trauma disorders. The bill, House Bill 6020, aims to allocate $50 million for research through a consortium involving states, manufacturers, and universities.

W. Bryan Hubbard, a Republican advocate, is driving bipartisan support for psychedelics, particularly ibogaine, by framing them as divinely inspired treatments for addiction and PTSD. His efforts influenced President Trump's executive order to accelerate psychedelic research, despite limited clinical data on ibogaine. Former Texas Governor Rick Perry and Joe Rogan also supported the push.

Scientists believe ibogaine can help veterans overcome PTSD. Ibogaine is a hallucinogenic substance that has shown promise in treating the condition. Researchers are exploring its potential as a therapeutic option.

The FDA announced ultra-fast review timelines for three psychedelic drugs, including psilocybin and methylone, following an executive order by the Trump administration to accelerate access to psychedelics for mental health treatments. The move aligns with growing support from Trump allies and Health Secretary Robert F. Kennedy Jr.'s advocacy for psychedelic therapies.

Donald Trump signed an executive order to accelerate research into hallucinogens and increase access, marking a significant moment for psychedelic studies. The move occurred on 'Bicycle Day,' the anniversary of the first LSD trip, and sparked both praise and concerns over access and protections.

The Trump administration reclassified state-licensed medical marijuana from Schedule I to Schedule III, aiming to expand research and patient access. President Trump also signed an executive order to expedite psychedelic drug research, citing potential benefits for veterans with mental health issues.

The Trump administration reclassified state-licensed medical marijuana from Schedule I to Schedule III, easing research and access. President Trump also signed an executive order to expedite psychedelic drug therapies for mental health, citing studies showing benefits for veterans.

Podcaster Joe Rogan revealed that President Trump called him a liberal during a White House event focused on advancing psychedelic drug research, including ibogaine. The event, which included an executive order signed by Trump, drew criticism from some attendees, as noted by guest Luis J. Gomez.

President Trump signed an executive order to expedite the review of psychedelic drugs, including ibogaine. The order aims to fast-track regulatory processes for these substances.

The US has issued an executive order to accelerate research on mind-altering drugs, including ibogaine, a psychedelic substance. While some researchers welcome the move, others caution that careful oversight is necessary to ensure safety and efficacy.

President Trump signed an executive order to fast-track psychedelic drug research after a text exchange with Joe Rogan, accelerating federal review of substances like ibogaine and LSD. The policy shift, led by Health Secretary Robert F. Kennedy Jr., aims to expedite FDA approvals and address mental health challenges, particularly for veterans.

President Trump signed an order to accelerate the review of psychedelics for treating mental health disorders, specifically endorsing psilocybin and ibogaine. The order aims to expedite research and regulatory processes for these substances.

President Trump, joined by Joe Rogan, signed an executive order directing the federal government to expedite the review and relax restrictions on psychedelics, including ibogaine, for potential therapeutic applications. The order aims to accelerate the development of psychedelic-based treatments by reducing regulatory barriers.

President Trump signed an executive order to expedite the review of psychedelic drugs like ibogaine, which has gained support from combat veterans and conservative lawmakers despite known safety risks. The move aims to accelerate access to these treatments, though concerns about their potential dangers remain.

President Trump signed an executive order to ease U.S. restrictions on psychedelic research, including ibogaine, a drug used in some countries to treat post-traumatic stress disorder.

Joe Rogan revealed he sent information about ibogaine to Donald Trump. The substance, ibogaine, is known for its potential in treating addiction but remains controversial.

President Donald Trump signed an executive order directing the FDA to expedite the review of psychedelic drugs like ibogaine, which U.S. military veteran groups claim can treat post-traumatic stress disorder (PTSD). The reform aims to accelerate access to medical research and treatment involving psychedelic substances.

President Donald Trump signed an executive order to accelerate the review of psychedelic drugs, including ibogaine, which is controversial due to safety risks but advocated for by veterans and conservative lawmakers. The FDA will fast-track approvals using national priority vouchers, marking the first time psychedelics receive such expedited review. The move aims to expand access to potential treatments for conditions like PTSD and opioid addiction.

President Donald J. Trump joked about requesting ibogaine during an executive order signing that directs the FDA to review psychedelic drugs designated as breakthrough therapy. The event highlighted a lighthearted moment amid a serious policy directive.

President Trump signed an executive order to facilitate research into ibogaine, a psychedelic drug used abroad for treating PTSD, according to CBS News sources. The order aims to open new pathways for studying the drug's therapeutic potential.

Trump is set to sign an executive order regarding ibogaine, a psychedelic drug used in Mexico and the Caribbean to treat PTSD, depression, anxiety, addiction, and brain trauma.